Chen Chih-Rung, Su Yu-Chi, Chen Hui-Chuan, Lin Yu-Ching
School of Medicine, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan.
Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704302, Taiwan.
Healthcare (Basel). 2023 Jul 6;11(13):1956. doi: 10.3390/healthcare11131956.
(1) Background: The purpose of this study was to determine whether the drooling of adult patients with diverse central nervous system diseases can be treated with botulinum toxin type A. (2) Methods: The Cochrane Library, MEDLINE, and Embase were all searched for studies that fit the inclusion criteria. The patients in the studies had to be adults (>18 years old), and the studies had to be randomized placebo-controlled trials, controlled trials, or prospective studies. Each study had to have enough quantifiable data available for meta-analysis. The primary outcome measure was the Drooling Severity and Frequency Scale (DSFS). (3) Results: The meta-analysis comprised three studies. A statistically significant difference in DSFS score between the treatment and control groups was observed in the meta-analysis, with an overall standardized mean difference of -0.9377 (95% CI, -1.2919 to -0.5836; < 0.0001). A total of seven studies were ineligible for inclusion in the meta-analysis and were only assessed as qualitative data. All qualitative studies showed a significant reduction in DSFS score a few weeks or months after the injection of botulinum toxin. (4) Conclusions: Botulinum toxin type A is safe and effective as a treatment for drooling in adult patients with central nervous system diseases.
(1) 背景：本研究旨在确定A型肉毒杆菌毒素能否治疗患有多种中枢神经系统疾病的成年患者的流涎症状。(2) 方法：检索考克兰图书馆、医学期刊数据库（MEDLINE）和荷兰医学文摘数据库（Embase），查找符合纳入标准的研究。研究中的患者必须为成年人（>18岁），且研究必须是随机安慰剂对照试验、对照试验或前瞻性研究。每项研究必须有足够的可量化数据用于荟萃分析。主要结局指标是流涎严重程度和频率量表（DSFS）。(3) 结果：荟萃分析纳入三项研究。荟萃分析观察到治疗组和对照组之间DSFS评分存在统计学显著差异，总体标准化平均差为-0.9377（95%置信区间，-1.2919至-0.5836；P<0.0001）。共有七项研究不符合纳入荟萃分析的条件，仅作为定性数据进行评估。所有定性研究均显示，注射肉毒杆菌毒素几周或几个月后，DSFS评分显著降低。(4) 结论：A型肉毒杆菌毒素作为治疗患有中枢神经系统疾病的成年患者流涎症状的方法是安全有效的。
